Literature DB >> 31030755

Tremella polysaccharide: The molecular mechanisms of its drug action.

Dandan Yang1, Yong Liu2, Lijuan Zhang3.   

Abstract

Tremella fuciformis is an edible medicinal mushroom well known as "Yiner" or "Baimuer" in China and has been used as a Chinese herb for many years. T. fuciformis polysaccharide (TFPS) has been identified as a major bioactive component. Different experimental conditions can obtain different TFPS fractions, which makes TFPS a mixture of different polysaccharides with the molecular weight ranging from 5.82×105Da to 3.74×106Da. The monosaccharides detected in TFPS include mannose, xylose, fucose, glucuronic acid, glucose, and galactose. One characterized TFPS chemical structure consists of a linear (1→3)-linked α-d-mannose backbone with highly branched β-d-xylose, α-d-fucose and β-d-glucuronic acid as the side chains. TFPS shows multiple physiological and healthy promoting effects including immunomodulation, antitumor, anti-oxidation, anti-aging, hypoglycemic, hypolipidemic, neuroprotection, and other effects. As a result, "Tremella Polysaccharide Enteric-coated Capsules" was approved by Chinese Food and Drug Administration (SFDA) in 2002 for treating cancer patients with leukopenia induced by chemotherapy and radiotherapy. It is also used as adjuvant drug for treating chronic persistent hepatitis and chronic active hepatitis. In this chapter, 113 independent studies involving in biochemical, pharmacological, and clinical studies of TFPS during the past 46 years (1972-2018) on the base of PubMed, CNKI (China National Knowledge Infrastructure) and Wanfang database search are summarized. TFPS shows efficacy for all types of human diseases in the reported clinical studies. The structure, molecular mechanisms of the immunomodulation, antitumor, anti-oxidation, anti-aging, hypoglycemic, hypolipidemic, preclinical and clinical efficacy are discussed to provide a general picture of TFPS as a clinically used drug.
© 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biological response modifier; Cancers; Chronic active hepatitis; Chronic persistent hepatitis; Leukopenia; Polysaccharide; Tremella fuciformis; Tremella polysaccharide enteric-coated capsules

Mesh:

Substances:

Year:  2019        PMID: 31030755     DOI: 10.1016/bs.pmbts.2019.03.002

Source DB:  PubMed          Journal:  Prog Mol Biol Transl Sci        ISSN: 1877-1173            Impact factor:   3.622


  6 in total

1.  Tremella fuciformis Polysaccharides Inhibited Colonic Inflammation in Dextran Sulfate Sodium-Treated Mice via Foxp3+ T Cells, Gut Microbiota, and Bacterial Metabolites.

Authors:  Yingyin Xu; Liyuan Xie; Zhiyuan Zhang; Weiwei Zhang; Jie Tang; Xiaolan He; Jie Zhou; Weihong Peng
Journal:  Front Immunol       Date:  2021-04-01       Impact factor: 7.561

Review 2.  Pathogen and host genetics underpinning cryptococcal disease.

Authors:  Carolina Coelho; Rhys A Farrer
Journal:  Adv Genet       Date:  2020-03-18       Impact factor: 3.880

3.  A review on the production, structure, bioactivities and applications of Tremella polysaccharides.

Authors:  Xia Ma; Meng Yang; Yan He; Chuntao Zhai; Chengliang Li
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

4.  Pro-Angiogenic Effects of Essential Oil from Perilla frutescens and Its Main Component (Perillaldehyde) on Zebrafish Embryos and Human Umbilical Vein Endothelial Cells.

Authors:  Fei Zhou; Ou Dai; Cheng Peng; Liang Xiong; Hui Ao; Fei Liu; Qin-Mei Zhou
Journal:  Drug Des Devel Ther       Date:  2021-12-11       Impact factor: 4.162

5.  New Hyaluronic Acid from Plant Origin to Improve Joint Protection-An In Vitro Study.

Authors:  Rebecca Galla; Sara Ruga; Silvio Aprile; Sara Ferrari; Arianna Brovero; Giorgio Grosa; Claudio Molinari; Francesca Uberti
Journal:  Int J Mol Sci       Date:  2022-07-23       Impact factor: 6.208

6.  Spinal cord injury can be relieved by the polysaccharides of Tricholoma matsutake by promoting axon regeneration and reducing neuroinflammation.

Authors:  Jun Liu; Feng Yang; Maofeng Cheng; Yan Zhang
Journal:  Neuroreport       Date:  2020-10-07       Impact factor: 1.703

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.